| Patent application number | Description | Published |
|---|
| 20080267281 | METHOD, DEVICE AND NETWORK ELEMENT FOR DECODING AN INFORMATION WORD FROM A CODED WORD - It is disclosed a method for decoding an information word from a set of coded words. The method comprises the steps of receiving a coded word, of selecting a coded word having the minimum distance from the received coded word from a pre-configured sub-set of the set of the coded words, wherein the sub-set is configured to at least two coded words having each other a distance higher than the minimum distance between the coded words of the set, and of decoding the information word from the selected coded word. | 10-30-2008 |
| 20100138711 | Equipment protection method and apparatus - Equipment protection of a switch matrix (SM) in a network node, which contains a number of matrix modules (M | 06-03-2010 |
| 20130028265 | UPDATE OF A CUMULATIVE RESIDENCE TIME OF A PACKET IN A PACKET-SWITCHED COMMUNICATION NETWORK - It is disclosed a method for updating a cumulative residence time of a synchronization packet received at a node of a packet-switched communication network. The cumulative residence time is equal to a cumulative sum of residence times of the packet at nodes interposed between a further node which has generated the packet and the node. The node comprises an ingress circuit and an egress circuit. The method comprises: receiving the packet at the egress circuit from the ingress circuit; at a timestamp generator of the egress circuit, generating a timestamp; at the egress circuit, calculating a virtual timestamp based on the timestamp and on an estimated variable delay that will be undergone by the packet due to buffering in a buffer located downstream the timestamp generator; and, at the egress circuit, using the virtual timestamp for updating the cumulative residence time, before transmitting the packet to a still further node. | 01-31-2013 |
| 20130101300 | POWER ADJUSTMENT OF IN-PHASE AND QUADRATURE COMPONENTS AT A COHERENT OPTICAL RECEIVER - It is disclosed an optical coherent receiver for an optical communication network. The optical coherent receiver is configured to receive a modulated optical signal and to process it for generating an in-phase component and a quadrature component. The optical coherent receiver comprises a power adjuster in turn comprising a multiplying unit and a retroactively connected digital circuit. The multiplying unit is configured to multiply the in-phase and quadrature components by in-phase and quadrature gains, respectively, thereby providing power-adjusted in-phase and quadrature components. The digital circuit is configured to compute: a common gain indicative of a sum of the powers of the power-adjusted in-phase and quadrature components; a differential gain indicative of a difference between the powers of the power-adjusted in-phase and quadrature components; and the in-phase and quadrature gains as a product and a ratio, respectively, between the common gain and the differential gain. | 04-25-2013 |
| 20140195878 | METHOD OF DECODING A DIFFERENTIALLY ENCODED PHASE MODULATED OPTICAL DATA SIGNAL - Proposed is a method of decoding a differentially encoded PSK modulated optical data signal carrying FEC encoded data values. The optical signal is corrected by an estimated phase offset. From the corrected signal, respective likelihood values for the FEC encoded data values are derived, using an estimation algorithm which accounts for a differential encoding rule used for differentially encoding the optical signal. The derived likelihood values are limited to a predetermined range of values. From the limited likelihood values, FEC decoded data values are derived, using an algorithm which accounts for a FEC encoding rule used for FEC encoding the FEC encoded data values. | 07-10-2014 |
| Patent application number | Description | Published |
|---|
| 20080280849 | Synergic Combinations Comprising a Quinoline Compound and Other Hiv Infection Therapeutic Agents - The invention relates to a combination comprising a quinoline compound or its sail, according to general formula (I) and at least one HIV infection therapeutic agent selected from the group consisting of entry inhibitors, reverse-transcriptase inhibitors, strand-transfer inhibitors, protease inhibitors, and maturation inhibitors. Said combination has therapeutic synergy in the treatment of an HIV infection compared with the quinoline compound, or HIV infection therapeutic agent alone. | 11-13-2008 |
| 20090169511 | Mucosal Bioadhesive SLow Release Carrier for Delivering Active Principles - A mucosal bioadhesive slow release carrier comprising an active principle and devoid of starch, lactose, which can release the active principal for a duration of longer than 20 hours. This bioadhesive carrier contains a diluent, an alkali metal alkylsulfate, a binding agent, at least one bioadhesive polymer and at least one sustained release polymer, as well as a method for its preparation. | 07-02-2009 |
| 20100266667 | MUCOSAL BIOADHESIVE SLOW RELEASE CARRIER FOR DELIVERING ACTIVE PRINCIPLES - A mucosal bioadhesive slow release carrier comprising an active principle and devoid of starch, lactose, which can release the active principal for a duration of longer than 20 hours. This bioadhesive carrier contains a diluent, an alkali metal alkylsulfate, a binding agent, at least one bioadhesive polymer and at least one sustained release polymer, as well as a method for its preparation. | 10-21-2010 |
| 20110039800 | PROLONGED RELEASE BIOADHESIVE THERAPEUTIC SYSTEMS - The present invention concerns a prolonged release bioadhesive mucosal therapeutic system containing at least one active principle, with an active principle dissolution test of more than 70% over 8 hours and to a method for its preparation. Said bioadhesive therapeutic system comprises quantities of natural proteins representing at least 50% by weight of active principle and at least 20% by weight of said tablet, between 10% and 20% of a hydrophilic polymer, and compression excipients, and comprising between 4% and 10% of an alkali metal alkylsulphate to reinforce the local availability of active principle and between 0.1% and 1% of a monohydrate sugar. | 02-17-2011 |
| 20110237563 | FAST DISSOLVING DRUG DELIVERY SYSTEMS - The present invention related to the administration of bioactive agents via oral fast dispersing/dissolving drug delivery systems for treating illnesses of patient with critical buccal condition, leading to difficulties in swallowing oral medicine forms and thus difficulties in treating said illnesses. Particularly, the present invention discloses the administration of bioactive agents via oral fast dispersing/dissolving drug delivery systems for treating illnesses of patient with dysphagia and/or odynophagia and/or aspiration risk. Another aspect of the present invention is the administration of bioactive agents via oral fast dispersing/dissolving drug delivery systems for the treatment of dysphagia and/or odynophagia and/or aspiration risk. | 09-29-2011 |
| 20120326350 | MUCOSAL BIOADHESIVE SLOW RELEASE CARRIER FOR DELIVERING ACTIVE PRINCIPLES - A mucosal bioadhesive slow release carrier comprising an active principle and devoid of starch, lactose, which can release the active principal for a duration of longer than 20 hours. This bioadhesive carrier contains a diluent, an alkali metal alkylsulfate, a binding agent, at least one bioadhesive polymer and at least one sustained release polymer, as well as a method for its preparation. | 12-27-2012 |
| 20120329817 | MUCOSAL BIOADHESIVE SLOW RELEASE CARRIER FOR DELIVERING ACTIVE PRINCIPLES - A mucosal bioadhesive slow release carrier comprising an active principle and devoid of starch, lactose, which can release the active principal for a duration of longer than 20 hours. This bioadhesive carrier contains a diluent, an alkali metal alkylsulfate, a binding agent, at least one bioadhesive polymer and at least one sustained release polymer, as well as a method for its preparation. | 12-27-2012 |
| 20130210841 | MUCOADHESIVE BUCCAL TABLETS FOR THE TREATMENT OF OROFACIAL HERPES - The present invention relates to the treatment and/or prevention of muco-cutaneous herpes simplex virus diseases using prolonged release mucoadhesive buccal tablets comprising an acyclic guanosine antiviral agent. These tablets are particularly-suitable for the treatment and/or prevention of orofacial herpes. | 08-15-2013 |
| 20130303556 | MUCOSAL BIOADHESIVE SLOW RELEASE CARRIER FOR DELIVERING ACTIVE PRINCIPLES - A mucosal bioadhesive slow release carrier comprising an active principle and devoid of starch, lactose, which can release the active principal for a duration of longer than 20 hours. This bioadhesive carrier contains a diluent, an alkali metal alkylsulfate, a binding agent, at least one bioadhesive polymer and at least one sustained release polymer, as well as a method for its preparation. | 11-14-2013 |
| 20130310335 | PROLONGED RELEASE BIOADHESIVE THERAPEUTIC SYSTEMS - The present invention concerns a prolonged release bioadhesive mucosal therapeutic system containing at least one active principle, with an active principle dissolution test of more than 70% over 8 hours and to a method for its preparation. Said bioadhesive therapeutic system comprises quantities of natural proteins representing at least 50% by weight of active principle and at least 20% by weight of said tablet, between 10% and 20% of a hydrophilic polymer, and compression excipients, and comprising between 4% and 10% of an alkali metal alkylsulphate to reinforce the local availability of active principle and between 0.1% and 1% of a monohydrate sugar. | 11-21-2013 |
| 20150133487 | TRITOQUALINE FOR USE IN THE TREATMENT OF CYSTIC FIBROSIS - This invention relates to tritoqualine for use in the treatment of cystic fibrosis or any one of its complications. The invention also relates to the method for the treatment of cystic fibrosis or any one of its complications by administering tritoqualine. The invention can be used to improve the condition of individuals with cystic fibrosis. | 05-14-2015 |
| Patent application number | Description | Published |
|---|
| 20080311171 | IMPLANTABLE POLYMERIC DEVICE FOR SUSTAINED RELEASE OF DOPAMINE AGONIST - The present invention provides compositions, methods, and kits for treatment of Parkinson's disease and other conditions for which treatment with a dopamine agonist is therapeutically beneficial. The invention provides a biocompatible nonerodible polymeric device which releases dopamine agonist continuously with generally linear release kinetics for extended periods of time. Dopamine agonist is released through pores that open to the surface of the polymeric matrix in which it is encapsulated. The device may be administered subcutaneously to an individual in need of continuous treatment with dopamine agonist. | 12-18-2008 |
| 20090162412 | IMPLANTABLE POLYMERIC DEVICE FOR SUSTAINED RELEASE OF DOPAMINE AGONIST - The present invention provides compositions, methods, and kits for treatment of Parkinson's disease and other conditions for which treatment with a dopamine agonist is therapeutically beneficial. The invention provides a biocompatible nonerodible polymeric device which releases dopamine agonist continuously with generally linear release kinetics for extended periods of time. Dopamine agonist is released through pores that open to the surface of the polymeric matrix in which it is encapsulated. The device may be administered subcutaneously to an individual in need of continuous treatment with dopamine agonist. | 06-25-2009 |
| 20120258161 | IMPLANTABLE POLYMERIC DEVICE FOR SUSTAINED RELEASE OF DOPAMINE AGONIST - The present invention provides compositions, methods, and kits for treatment of Parkinson's disease and other conditions for which treatment with a dopamine agonist is therapeutically beneficial. The invention provides a biocompatible nonerodible polymeric device which releases dopamine agonist continuously with generally linear release kinetics for extended periods of time. Dopamine agonist is released through pores that open to the surface of the polymeric matrix in which it is encapsulated. The device may be administered subcutaneously to an individual in need of continuous treatment with dopamine agonist. | 10-11-2012 |
| 20150151029 | IMPLANTABLE POLYMERIC DEVICE FOR SUSTAINED RELEASE OF DOPAMINE AGONIST - The present invention provides compositions, methods, and kits for treatment of Parkinson's disease and other conditions for which treatment with a dopamine agonist is therapeutically beneficial. The invention provides a biocompatible nonerodible polymeric device which releases dopamine agonist continuously with generally linear release kinetics for extended periods of time. Dopamine agonist is released through pores that open to the surface of the polymeric matrix in which it is encapsulated. The device may be administered subcutaneously to an individual in need of continuous treatment with dopamine agonist. | 06-04-2015 |
| Patent application number | Description | Published |
|---|
| 20110263923 | SPACERS FOR USE IN BRACHYTHERAPY, RADIOTHERAPY, AND OTHER MEDICAL THERAPY - Spacers for use in brachytherapy, radiotherapy, and other medical therapy, which can be used to improve a patient's outcome, assist in treating difficult cases and/or combine multiple modalities that are currently performed separately into a single procedure. In accordance with an embodiment, a spacer is formed of an encapsulating material in a generally cylindrical or elongated shape. One or more regions are formed within the spacer for receiving and retaining therapeutic loads, such as radiation sources and/or pharmaceutical therapeutic loads, and/or any other substances that a physician might select to treat a patient, such as drug liquids, powder or particles (e.g., microparticles or nanoparticles), with the particles or powders combined with binders, such as polyacrylamide, that are selected to retain and gradually disperse the powder or particles at a desired rate. Such regions can be formed at various locations within the spacer, and can have various shapes depending on the particular design and intended usage, including, for example, bores, end cavities, wells, ports, slots and/or pockets. The outer surface of the encapsulating material can optionally include one or more fins, ribs or other physical protuberances or features that improve the fixity of the spacer when implanted within a patient's body. When implanted into the body, the spacer helps provide proper placement and spacing such as symmetrical and/or asymmetrical placement and spacing of the radiation sources and/or pharmaceutical therapeutic loads. | 10-27-2011 |
| Patent application number | Description | Published |
|---|
| 20110120606 | PNEUMATIC TIRE WITH TREAD - The present invention is directed to a pneumatic tire comprising a ground contacting tread, the tread comprising a rubber composition comprising
| 05-26-2011 |
| 20110146859 | TIRE WITH COMPONENT CONTAINING CARBON NANOTUBES - The present invention is directed to a method of conducting static electricity in a pneumatic tire, comprising the steps of mixing a rubber compound comprising at least one diene based rubber, from 60 to 150 phr of precipitated silica, less than 40 phr of carbon black, and from 1 to 10 phr of carbon nanotubes having a length of at least 5 microns; forming a tire tread from the rubber compound; and including the tire tread in the tire; wherein the volume resistivity of the tire tread is less than 1×10 | 06-23-2011 |
| 20110275751 | PNEUMATIC TIRE WITH TREAD - The present invention is directed to a pneumatic tire comprising a ground contacting tread, the tread comprising a rubber composition comprising
| 11-10-2011 |
| 20140336330 | PNEUMATIC TIRE WITH TREAD - The present invention is directed to a pneumatic tire comprising a ground contacting tread, the tread comprising a rubber composition comprising
| 11-13-2014 |
| 20150148477 | FUNCTIONALIZED POLYMER, RUBBER COMPOSITION AND PNEUMATIC TIRE - The present invention is directed to a functionalized elastomer comprising the reaction product of a living anionic elastomeric polymer and a polymerization terminator of formula I | 05-28-2015 |
| Patent application number | Description | Published |
|---|
| 20140279832 | SYSTEMS, DEVICES, AND METHODS FOR GENERATION OF CONTEXTUAL OBJECTS MAPPED BY DIMENSIONAL DATA TO DATA MEASURES - This disclosure in part describes systems, devices, and methods for implementing a unification mechanism that enables the unification of various data sets, which can permit greater collaboration between users of a data management platform. For example, a system can be configured to enable a user to add or associate a contextual object with a data measure. In associating the contextual object with the data measure, the system can store the contextual object with the unique dimension coordinates that are associated with data measure. Other users of the system may, in turn, access the data measure and be shown the contextual object associated with the data measure. | 09-18-2014 |
| 20150278392 | SYSTEMS, DEVICES, AND METHODS FOR GENERATION OF CONTEXTUAL OBJECTS MAPPED BY DIMENSIONAL DATA TO DATA MEASURES - This disclosure in part describes systems, devices, and methods for implementing a unification mechanism that enables the unification of various data sets, which can permit greater collaboration between users of a data management platform. For example, a system can be configured to enable a user to add or associate a contextual object with a data measure. In associating the contextual object with the data measure, the system can store the contextual object with the unique dimension coordinates that are associated with data measure. Other users of the system may, in turn, access the data measure and be shown the contextual object associated with the data measure. | 10-01-2015 |
| 20160103903 | SYSTEMS, DEVICES, AND METHODS FOR GENERATION OF CONTEXTUAL OBJECTS MAPPED BY DIMENSIONAL DATA TO DATA MEASURES - This disclosure in part describes systems, devices, and methods for implementing a unification mechanism that enables the unification of various data sets, which can permit greater collaboration between users of a data management platform. For example, a system can be configured to enable a user to add or associate a contextual object with a data measure. In associating the contextual object with the data measure, the system can store the contextual object with a parameter indicative of the unique dimension coordinates that are associated with the data measure. Other users of the system may, in turn, access the data measure and be shown the contextual object associated with the data measure. | 04-14-2016 |
